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Abstract Epigenetic modification acetylation or deacetylation of 
histone considered as an important element in various disorders. Histone 
acetyltransferases (HATs) and histone deacetylases (HDACs) are the enzymes 
which catalyse the acetylation and deacetylation of histone respectively. It helps 
in regulating the condensation of chromatin and transcription of genes. Lysine 
acetylation and deacetylation present on the nucleosomal array of histone is 
the key factor for gene expression and regulation in a normal working living 
cell. Modification in histone protein will lead to the development of cancer 
and can cause various neurodegenerative disorders. To safeguard the cells or 
histone proteins from these diseases histone deacetylase inhibitors are used. In 
this review, the main focus is upon the role of histone deacetylases inhibitors 
in various diseases.
Keywords: Epigenetic; Histone; Acetylation; Deacetylation; Lysine; Histone 
deacetylases inhibitors
1. INTRODUCTION 
Eukaryotic cell nuclei contain a highly alkaline protein known as histone which 
helps DNA to attain its helical structure. An octad of four core histones forms a 
fundamental subunit of chromatin termed as the nucleosome (Kornberg, 1999; 
Ito et al. 2000). The nucleosome represents a principle protein-nucleic acid 
relationship of chromatin, (Kornberg, 1999). Four core histones are H3/H4 
tetramer and two H2A/H2B dimers (Ito et al. 2000; Strahl, 2000). A chromatin 
strand consists of 146 base pairs of DNA wrapped around the histone protein 
give rise to the nucleasomal array (200bp). All these four core histones all 








helix. This N-terminal of histones is prior to modification during activation 
of gene transcription and gene expression. The various modifications that 
can take place are methylation, phosphorylation, and the acetylation. Among 
this modification, acetylation is widely occurring and understandable 
modification of histone proteins. Modifications of histones H3 and H4 are 
much more extensively characterized than those of H2A and H2B (Wade, 
2001). Acetylation mainly takes place on the amino acid Lysine (Lys). Other 
post-translational modifications of histone include methylation of Lys and 
arginine, ubiquitination of lysine phosphorylation of serine and ubiquitination 
of lysine (Zhang, 2001; Jenuwein, 2001). On histone H3 important positions 
for acetylation are Lys9 and 14 and on histone H4 positions for acetylation 
are Lys5, 8, 12, 16 (Bjerling et al. 2002). Acetylation of histone is affected 
by two classes of enzymes-histone acetyltransferases (HATs) and histone 
deacetylases (HDACs). This acetylation and deacetylation determine the gene 
expression (Ito et al. 2000; Wade, 2001; Forsberg, 2001)
2. HISTONE ACETYL TRANSFERASE ACETYLATION
Acetylation by HATs leads to the uncoiling of the nucleosomal array, which 
is due to the development of negative charge on histone due to modification 
process destabilization of the inter-nucleosomal interactions and also due to 
interaction of phosphate backbone of DNA with histone. Hyperacetylation 
increased the accessibility of chromatin to transcriptional factor (Cress, 2000).
Generally, hyperacetylation leads to increased transcriptional activity of 
a gene, whereas hypoacetylation cause repression of gene expression (Ito 
et al. 2000; Wade, 2001; Forsberg, 2001). A pattern of post-translational 
modifications (acetylation) makes a “code” which is recognized and translated 
by nonhistone proteins and multiprotein complexes. These complexes are 
important aspects for transcription-activation and transcription-repression. 
HATs are categorised into two big families GNAT (Gcn5-related N-acetyl 
Transferase) and the MYST (Moz, Ypf2-Sas3, Sas2, Tip60) group and one 
small family p300/CBP (CREB Binding proteins) family. Nonhistone protein 
substrate which is targeted by HATs enzyme is collectively termed as FATs 
(Factor acetyltransferases) including p53, E2F, and GATA1 9 (GATA-binding 
factor 1) (Roth et al, 2001).
3. HISTONE DEACETYLASES
The interaction of histone deacetylases with histone tends to increase 
electrostatic bond of histones which contains both positively and negatively 
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restrains transcription of gene by controlling the penetrability of transcription 
factors (Polo and Almouzni, 2005) accompanied by removing neutralizing 
acetyl groups from the histone Lys tail (Timmermann et al. 2001). HDACs 
categorized in two major classes. The human class 1 deacetylases contains 
enzymes similar to yeast transcriptional regulator such as HDACs 1, 2, 3 and 8 
(Joseph et al. 2000). They share homology in their catalytic sites (De Ruijter et 
al. 2003). All class 1 enzymes which are present everywhere in human cell lines 
and tissues have nuclear location. Another one is human class 2 deacetylase; 
co-enzymes in this category are similar to HDA1P. Another class which is of 
class 2 is divided in different sub classes such as class 2a (HDAC4, 7, 5 and 9) 
and class 2b (HDAC6 and 10) (Glass, 2000). These share similarities in two 
regions, the one is C-terminal catalytic domain and another one is N-terminal 
regulatory domain (Grozinger et al. 2001).
Class 2 enzymes have tissue specific expression and free to move across 
nucleus and cytoplasm. Class 2 also helps in introduction of acetyl group in 
non-histone proteins. Some other categories are the sirtuins (SIRTI-7) family 
and maize HD2 (Grozinger et al. 2001; Verdel et al. 1999). Proteins in SIRT 
group are in much resemblance with yeast SIR2 family of proteins (Glass 
and Rosenfeld, 2000). HDAC11 which is new member of HDAC family was 
discovered recently (Verdel et al. 1999).
HDACs enzymes have important role in regulation of basic process of cell 
cycle growth and programmed cell death (Robertson et al. 2000). HDAC also 
have important function in cancer growth. It is not only restricted to histone 
deacetylation (Juan et al. 2000). Down regulation of post translational histone 
modifications leads to failure of gene transcription. A study showed the loss of 
acetylated Lys16 of H4 is normal even in cancer of human (Fraga et al. 2005).
4. HISTONE DEACETYLASE INHIBITORS
The HDAC inhibitors (HDACi) consist of 3 parts: a ‘can’ part of ‘surface 
recognition domain’, which opens gate of active site; a group of zinc binders 
which chelates zinc ion at the active site and is helpful for catalytic function; 
and a ‘linker’ region which bring together the two. The shape of HDAC 
inhibitors have been refined in various studies of homologue of trichostatin 
A (TSA) and suberoylanilide hydroxyamic acid (SAHA) (Finnin et al. 
1999). The crystal shape of hydroxamate complex which is also known as 
HDAC8 has been mentioned (Somoza JR et al. 2004). The studies in various 
labs explored the 3-d structure of catalytic site in HDACs and have also 
explained about the mechanism of acetylated lysine substrates deacetylation. 








base of catalytic pocket. Various HDAC enzymes have different biological 
activities and HDAC1 and HDAC2 class plays crucial role in transformation 
of proliferation of cell leading to obtain selective HDAC inhibitors. Tubacin 
which is a small molecule is created that mainly stops HDAC6 activity and 
lead to accumulation of acetylated alpha-tubulin, but it doesn’t change and 
stops cell cycle progression and histones acetylation (Haggarty SJ et al. 2003).
HDAC inhibitors discovered till now can be classified into different 
structural classes which include hyroximates, different cyclic peptides, some 
of aliphatic acids and also benzamides (Marks PA et al. 2004). TSA, the first 
natural hydroximate product was discovered which inhibit HDACs. SAHA 
looks alike TSA structurally and is nanomolar antagonist of HDAC class 1 
and 2 (Richon VM et al. 1996). HDAC class 3 is neither inhibited by TSA or 
SAHA.
CBHA (Carboxycinnamic-m acid Bis-hydroxamide- HDAC inhibitor) 
which is also known as M-carboxycinnamic acid bishydroxamide is a potent 
HDAC inhibitor. It shows the structural basis for different derivatives such as 
LAQ824 and sulfonamide. PXD-101 also inhibit class 1 and 2 HDACs in very 
small concentrations. The cyclic peptides are structurally very complex group 
of HDAC inhibitors. They include the natural product which is depsipeptide 
also known as FK228, another molecule apicidin and sum molecules of chaps 
group. They all are active in small concentrations. FK228 is a pro drug of red Fk 
which is an active agent. Other cyclic tetrapeptides which have trifluoroethyl 
and pentafluoroethyl ketone and also contains zinc binding functional groups 
are synthesized and are strong HDAC inhibitors (Jose B et al. 2004).
Vorinostat is also structurally similar to TSA (Richon et al. 1998). The 
different types of aminosuberoyl hydroxamic acids have been established 
recently which modify proliferation of cells at low concentrations (Belvedere 
et al. 2007). The first therapeutically FDA approved HDAC inhibitor is 
vorinostat. Vorinostat is inhibitors of class 1 and class 2 HDAC proteins (Duvic 
et al. 2007). The Novartis discovered product panobinostat is analogue of 
hydroxamic acid of CBHA (Marks et al. 2007). Another HDACi, the IF2357 
have a hydroxamic acid moiety attached to benzene ring (Leoni et al. 2005). 
Another series of HDACi at small concentrations are aryloxyalkanoic acids 
which have been recently developed (Marson et al. 2007).
Cyclic peptide is a class of structurally complex group and are HDACi 
which consist different herbal drugs such as depsipeptide, another name is 
FK228 and romidepsin, manufactured by Gloucester Pharmaceutical Inc (Jose 
B et al. 2004). Apicidin and other cyclic hydroxamic acid which contains 
peptide group are all active at low amount. Depsipeptide also known as FK228 
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aliphatic chain to a hydroxamic acid is new HDACi and are active at very 
minute concentrations such as millimolar (Liu T et al. 2007).
Another class of compounds such as aliphatic acids which contains butyrate, 
phenylbutyrate and valproic acid, these all are weak antogonist of the HDACs 
and have action at very low concentrations (Xu W et al. 2005). Drugs like 
valproic acid and phenyl butyrate have recently shown activity as HDACi. Apart 
from that they are used in market for non-oncological uses. Pivaloyloxymethyl 
butyrate also known as AN-9 is manufactured by Titan Pharmaceutical, Inc. It 
is crucial pro drug for butyric acid (Rasheed WK et al. 2007).
MS-275 which is manufactured by Syndax Pharmaceutical Inc is 
derivative of benzamide. Another one is MGCD0103 and is dihydobromide 
salt of aminophenyl benzamide (Gelmon K et al. 2005). M-275 shows more 
inhibitory action at HDAC1 in comparison to HDAC3 and it have low effect 
against HDAC6 and very low at HDAC8. Other molecules like SK7041 
and SK7068, they only show action against HDAC1 and HDAC2. Another 
compound name tubacin which is a small molecule, it particularly inhibits the 
activity of HDAC6 and lead to accumulation of acetylated tubulin. It doesn’t 
stop cell cycle progression (Haggarty SJ et al. 2003).
5. MECHANISM OF HISTONE DEACYTYLASE INHIBITORS
HDACi work induce inhibition of cell growth by causing introduction of acetyl 
group in histones proteins which help in expression of gene, cell growth, cell 
migration and cell death (Xu et al. 2007). They work by inducing apoptosis 
by energizing both intrinsic pathway and extrinsic pathway. They mediate 
tumours cell death due to introduction of apoptosis which result in caspase 
activation and cell death. Extrinsic pathway start with the attachment of the 
ligand likely to be as Fas ligand, TNF (Tumour necrosis factor) ligand and 
TNF related apoptosis inducing ligand also known as TRAIL (Tumour necrosis 
factor-related apoptosis -inducing ligand) on the surface of cell death receptor 
(DR) (Johnstone et al. 2002). Intrinsic pathways works through destruction of 
membrane of mitochondria of cell by stress like radiation, chemical therapies 
and withdrawing growth factors. HDACi also works by blocking angiogenesis 
of tumour by stopping HIF which is known as hypoxia inducible factors. 
Hypoxia regulates expression of gene in VEGF (Vascular endothelial growth 
factor) by balancing factors such as HIF 1-apha and VHL (Von hippl Lindau) 
which is tumour suppressor gene. In conditions like hypoxia TSA work by 
upregulating VHL and p53 and blocking angiogenesis by downregulating 
VEGF and HIF 1-alpha (Kim et al. 2001). These HDACi shows anti-angiogenic 








(Qian et al. 2006). HDACi also cause destruction of DNA with making 
changes in chromatin conformation at histone acetylation. Another mechanism 
is production of ROS which is also known as reactive oxygen species which 
lead to cell death by damage to DNA. HDACi increases production of ROS by 
downregulation of thioredoxin (Trx) (Marks et al. 2006).
Control over gene expression is primarily kept by HATs and HDAC. The 
stability between the HATS AND HDACs activity is necessary for normal 
cellular function. Deregulation as over expression and hypo expression of 
HDACs/HATs is found to be causative and progressive agents in various 
cancers and neurodegenerative diseases. 
6. ROLE OF HISTONE DEACETYLASE IN CANCER
Histone acetylation and deregulation of methylation of DNA are considered as 
the feature for the development of cancer and further causing deregulation of 
gene transcriptional factors. Acetylation of Lys16 (K16-H4) and Lys20 (K20-H4) 
residues are responsible for the relaxed state of chromatin plus the activation 
of the transcription of genes and has been correlated with genomic functions 
(Polo, 2005; Vidanes et al. 2005). Deacetylation of the Lys 16, 20 causes are 
responsible interactions between the histones (negatively charged) and DNA 
(positively charged) will out turn the compressed structure of chromatin and 
silence the genes (Johnstone, 2002; Iizuka, 2003). In tumours of GIT, it has 
been achieved that decrease in acetylation occurs in tumour development as 
well as in aggregation of tumour and metastasis (Yasui et al. 2003).
There are many ways for HDACs to regulate the expression of genes. In 
the absence of ligand they form corepressor complexes like N-CoR, SMRT, 
and mSin3 (Glass and Rosenfeld, 2000) and mark particular genomic sites by 
binding to the transcriptional factors, receptors of a nucleus and some specific 
genes like MBDs (methyl -CpG-binding domain), DNMTs (DNA methyl 
Transferase), and HMTs (histone methyl Transferase). Binding of these factors 
will cause the suppression of genes (Jones et al. 1998; Nan et al. 1998).
Translocation of the chromosome is a genetic feature of hematological 
malignancies as it yields the fusion proteins (RAR-PML, RAR-PLZF) which 
interacts with the RARE’s and initiate the HDAC repressor complex to repress 
the gene expression by inhibiting the retinoic acid so as to improve the normal 
functioning of myeloid cells (Lin et al. 2001).
In humans there are different types of HDACs which are responsible for 
tumourigenesis. Elevation of HDAC1 expression is found in GIT (Choi et al. 
2001), colon (Wilson et al. 2006), prostate (Halkidou et al. 2004), colorectal 
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is also elevated in colon cancer (Zhang et al. 2004) and HDAC6 levels are also 
elevated in the breast (Wilson et al. 2006). The SIRT1 plays a crucial role in 
cancer as its level is seen to be either increasing or decreasing in cancerous cells. 
As in lung cancer, prostate cancer and in leukemia the level of SIRT1 is tend 
to be increasing, whereas in colon cancer there is an attenuation in the level of 
SIRT1 (Yeung et al. 2004; Kuzmichev et al. 2005; Bradbury et al. 2005; Ozdag 
et al. 2006). HDAC inhibitors promote p21 expression; p21 regulates p53 which 
is a tumour suppressor. They also inhibit the proliferation of the cell.
Following are some novel inhibitors which can be used in various kind of 
cancer:
6.1 1, 3, 4-oxadiazolealanine.
Pidugu et al prepared the compound (R)-2-Amino-N-((5-phenyl-1, 3, 
4-oxadiazol-2-yl) methyl) propanamide (10b) (Pidugu et al. 2016) and 
considered as a potent HDAC8 inhibitor for the treatment of cancer (Gryder et al. 
2012). Bax, Bcl2, cytochrome c, and PARP are the apoptotic proteins. The Bcl2 
and Bax proteins generates the apoptosis, the levels of Bcl2 tends to decrease 
in cancerous cells leading to the formation of homodimers of Bax generating 
apoptosis in cancerous cells. The HDAC8 inhibitor dose-dependently promotes 
the expression of p21 in cancer cells which further inhibits the CDK1 expression. 
The compound also contributes to the increase in the level of cytochrome c and 
breakage of PARP which further inhibits the CDK1 expression by increasing 
the expression of p21 in cancer cells. The compound also activates the caspase 
3 and 9 in cancerous cells (Pidugu et al. 2017).
In cancer cells, p53 is a protein which suppresses the tumour and induces 
apoptosis in cancer cells (Chen et al. 2016). Protein p53 also promotes the 
expression of p21 which inhibits CDK1/CDK complex and promotes apoptosis 
(Zhang et al. 2009). There are two apoptotic pathways: extrinsic pathway and 
intrinsic pathway. The extrinsic pathway is disputed due to the over expression 
of the Bcl2 proteins and the intrinsic pathway conclusion is the damage to 
the mitochondrial membrane which leads to the discharge of cytochrome c 
and activation of caspase-3 due to breakage of PARP and fragments of DNA 
(Naseri et al. 2015).
6.2 BEBT-908
The PTEN (tumour suppressor) levels are controlled by PI3K-Akt pathway 
by altering its transcriptional activity. Akt pathway activates the NF-ᵏB 
transcriptional factor which regulates PPARβ/δ agonist and TNα which in 








p-AKT interpretation and considered as a potent PI3K and HDAC inhibitor. 
BEBT-908 activates mitochondrial-mediated pathways by persuading 
apoptosis in the cells (Li et al. 2017). BEBT-908 also activates G1 phase in 
cell cycle captured in the cells. HDAC inhibitors typically induce G1 cell cycle 
arrest through the upregulation of the cyclin-dependent kinase inhibitor p21 
(Yazbeck et al. 2015). HDAC inhibitors can also activate the mitochondria-
mediated apoptotic pathway and regulate the equilibrium between pro- and 
anti-apoptotic proteins (Rikiishi, 2011; Zhao et al. 2005).
6.3 Diallyl Trisulfides
DATS is HDAC inhibitor which alters the HIF-1α (Hypoxia-inducible factor 
1) interpretation in tumour cells. HIF-1α manages homeostasis via stimulation 
of the transcriptional factors (Mahon et al. 2001) of the targeted genes such 
as ANGPTL4, LOXL4, and LOX under hypoxic conditions (Wei et al. 2017). 
Development of tumour cells initiates the demand of oxygen in the cells and 
points to angiogenesis (Mazure et al. 2006). Excessive expression of HIF-1α 
leads to inflammation and diminish the capability of cells to migrate (Solinas 
et al. 2009).
The stimulation of the HIF-1α protein is reduced by DATS by controlling 
the levels of Trx-1 in the cancer cells. In the case of breast cancers, the levels of 
the Trx1 protein are very high. DATS adequately inhibited HIF-1α to abolish 
development of breast cancer (Wei et al. 2017). The Trx1 system is highly 
expressed in breast cancers (Lincoln et al. 2003; Cha et al. 2009) and Trx1 is 
considered as the marker for breast cancer (Park et al. 2014).
7.  ROLE OF HISTONE DEACETYLASE INHIBITORS IN 
NEURODEGENERATIVE DISORDERS.
7.1 Parkinson’s disease 
In PD brain, dieldrin and paraquat are the neurotoxins which cause acetylation 
of histone proteins. Not all but H2AK5, H3K9 and H4K5 are implicated in 
the histone acetulation (Song et al. 2010; Song et al. 2011). P25/Cdk5 caused 
neuronal death by inhibiting and deregulation of HDAC1. In an in vivo model 
for ischemia protection HDAC1 act as potentially protective against DNA 
damage and cultured neuron’s neurotoxicity (Kim et al. 2008). Neurotoxicity 
caused by transcriptional genes (BDNF, GDNE, HSP70, and TH+-IR), 
α-synuclein and MPP+ is inhibited by using HDAC inhibitors (Harrison and 
Dexter, 2013). A study of DAT promoter in the cultured rat N27 cell shows 
a significant role of valproate in regulating DAT expression via elevating the 










In AD brain, memory destruction, emotional defects and loss of neuron is 
caused due to the enhanced level of Aβ proteins which further activates the 
GSK-3β. GSK-3β stimulation leads to phosphorylation of tau proteins (Mucke 
et al. 2012). The HDAC proteins are also indulged in the progression of the 
AD by conducting the histone acetylation which alters the gene expression and 
alleviates the emotional balance and destruction of memory (Stridh, 2010). 
Inhibitors of HDAC inhibit the hyperphosphorylation of tau achieved by Aβ 
protein activation. HDAC inhibitors also allocate the gene expression via 
activation of proteins like GluR1 (glutamate receptor 1), PSD95 (postsynaptic 
density protein 95), MAP2 (microtubule-associated tubule 2), etc. (Xu et al. 
2011). Various pan-HDAC inhibitors interact with the HDAC proteins that 
include class I, II and IV (Green et al. 2008).
EVP-0334 enhances both short and long-term memories in mice. Histone 
deacetylase enzyme unwinds the DNA for effective gene expression. EVP-0334 
as histone deacetylase inhibitor, prevents the removal of the acetyl group and 
maintains the structure of DNA but it loses the compact structure of chromatin 
which is more open to gene expression (Leventhal et al. 2008). HDACi has 
both neuroprotective and neurodegenerative properties (Graff et al. 2013). 
Neuroprotection can be achieved by two ways: activation of transcriptional 
genes and the other works by maintaining the protein homeostasis comprising 
various pathways to be involved in controlling protein synthesis to achieve 
stability and functional properties of the proteasome (Hahnen et al. 2008).
7.3 Ischemic stroke
Stroke is caused due to various mechanisms such as excitotoxicity, 
inflammation, ionic imbalance and oxidative/nitrosative stress (Lo et al. 2003). 
Activation of microglia and infiltered leukocytes consisting of macrophages 
cause inflammation in the ischemic brain and leads to degeneration of neurons. 
Microglia on activation releases the proinflammatory mediators which further 
cause obstruction to brain and excitotoxicity (Gregersen et al. 2000). HDAC 
inhibitors such as valproic acid, sodium butyrate, and hydroxamine acid 
trichostatin decrease the growth of the cell and contribute to the differentiation 
of the cells. Sodium butyrate and trichostatin exhibits neuroprotective effects 
(Kim et al. 2007). HDAC inhibitors cause the hyperacetylation of the proteins 
and change the gene expression. Valproic acid suppresses the inflammation 
caused by microglia and LPS by suppression of the excretion of TNF-α and 
preparation of NO. HDAC inhibitors also decrease the p53 levels and levels of 









Huntington disease is a dynamic illness of the brain which causes loss of control 
in movement, emotional problems, and loss of cognition (Shen et al. 2008). 
In HD brain the histone enzymes alters the frame of chromatin and regulate 
the expression of the genes. Enzyme H2A is responsible for the acetylation, 
whereas the H2B is responsible for the methylation, the H3 is responsible 
for the phosphorylation and the H4 is responsible for the ubiquitination, and 
sumoylation of the histone that affects the stability of chromosome, mitosis, 
and transcription 46 (Tanny et al. 2007). Acetylation and methylation of the 
lysine 9 and 14 on H3 lead to transcription and silencing of genes respectively 
(Nakayama et al. 2001). Phosphorylation is also correlated with the gene 
transcription 46 (Nowak and Corces et al. 2004).
The networking between HAT and HDAC regulates the acetylation and 
deacetylation of histone 47. HAT increases the transcription of genes and 
the HDAC withdraws the acetyl group causing the genes to repress (Marks, 
2010). Polyglutamine proteins accumulation in the nucleus will have abnormal 
interactions with nuclear proteins altering the transcription of genes (Li, 
2004). The mutated htt connects the transcriptional factors like CBP, TBP, p53, 
and sp1 to destroy the functional activity of mitochondria by attenuating the 
expression of PGC-1 alpha which controls the biogenesis of mitochondria. 
HDAC inhibitors like SAHA and sodium butyrate increases the acetylation 
of histone proteins and slowed the evolution of degeneration of neurons. 
Mutant Htt decreases the levels of transcriptional factors as well as the level 
of acetylation by segregating the co-activators like CBP and making their 
aggregates (Sadri-Vakili et al. 2006).
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